Sanofi is a French pharma giant that discovers, makes, and sells prescription drugs, vaccines, and over-the-counter health products worldwide. Think of it as a medicine factory covering everything from multiple sclerosis treatments to flu shots and allergy pil
Sanofi's money comes from selling drugs and vaccines across three divisions, with annual revenue of EUR 46.72B in 2025. Gross margins run around 72%, showing strong pricing power, though net margins fluctuate quarterly—hitting 36.7% in one 2025 quarter but dro
Sanofi's vaccine portfolio and specialty drugs like Dupixent create high switching costs for doctors and patients, backed by patents and regulatory approvals that block generic competition. However, patent expirations on key drugs and competition from Pfizer,
Sell (sector percentile 22) — value A-, growth C-, profitability B+, momentum D, revisions C-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Expands indication to infants, strengthening meningococcal prevention and market position
Dupixent tops €5B quarterly sales; new CEO's first address focuses on pipeline revival
Market eyes Sanofi's €14-15B M&A budget for 2026, potential ABVX acquisition
Market discusses Sanofi's cash position and potential acquisition of ABVX
Company restructures top leadership team to focus on business units and strategic execution
Sanofi and Aqemia announced expansion of multi-year research collaboration in small molecule drug invention.
First anticancer treatment via on-body injector, offering new option for multiple myeloma patients
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
